EA201690171A1 - Улучшенный способ получения моноклональных антител - Google Patents
Улучшенный способ получения моноклональных антителInfo
- Publication number
- EA201690171A1 EA201690171A1 EA201690171A EA201690171A EA201690171A1 EA 201690171 A1 EA201690171 A1 EA 201690171A1 EA 201690171 A EA201690171 A EA 201690171A EA 201690171 A EA201690171 A EA 201690171A EA 201690171 A1 EA201690171 A1 EA 201690171A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- improved method
- monoclonal antibodies
- obtaining monoclonal
- provides
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IN2014/000450 WO2015004679A1 (en) | 2013-07-06 | 2014-07-07 | Improved process for production of monoclonal antibodies |
| IN2285MU2013 IN2013MU02285A (enExample) | 2013-07-06 | 2014-07-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201690171A1 true EA201690171A1 (ru) | 2016-06-30 |
Family
ID=51794933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201690171A EA201690171A1 (ru) | 2013-07-06 | 2014-07-07 | Улучшенный способ получения моноклональных антител |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20160215319A1 (enExample) |
| EP (1) | EP3019528A1 (enExample) |
| JP (1) | JP2016526385A (enExample) |
| CN (1) | CN105431454A (enExample) |
| AR (1) | AR096839A1 (enExample) |
| AU (1) | AU2014288811B2 (enExample) |
| BR (1) | BR112015032800A2 (enExample) |
| CA (1) | CA2917484A1 (enExample) |
| EA (1) | EA201690171A1 (enExample) |
| HK (1) | HK1218297A1 (enExample) |
| IL (1) | IL243011A0 (enExample) |
| IN (1) | IN2013MU02285A (enExample) |
| MX (1) | MX2016000123A (enExample) |
| NZ (1) | NZ715246A (enExample) |
| SG (1) | SG11201510342VA (enExample) |
| TW (1) | TW201514305A (enExample) |
| WO (1) | WO2015004679A1 (enExample) |
| ZA (1) | ZA201509334B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9062106B2 (en) | 2011-04-27 | 2015-06-23 | Abbvie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
| US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
| WO2013158273A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Methods to modulate c-terminal lysine variant distribution |
| WO2013158279A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Protein purification methods to reduce acidic species |
| US9249182B2 (en) | 2012-05-24 | 2016-02-02 | Abbvie, Inc. | Purification of antibodies using hydrophobic interaction chromatography |
| US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
| SG11201507230PA (en) | 2013-03-12 | 2015-10-29 | Abbvie Inc | Human antibodies that bind human tnf-alpha and methods of preparing the same |
| US10023608B1 (en) | 2013-03-13 | 2018-07-17 | Amgen Inc. | Protein purification methods to remove impurities |
| WO2014151878A2 (en) | 2013-03-14 | 2014-09-25 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides |
| US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
| EP3052640A2 (en) | 2013-10-04 | 2016-08-10 | AbbVie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
| US9085618B2 (en) * | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
| US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
| WO2015073884A2 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
| WO2017122157A1 (en) * | 2016-01-14 | 2017-07-20 | Dr. Reddy’S Laboratories Limited | Cell culture process |
| US20200087390A1 (en) | 2016-12-21 | 2020-03-19 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| JP2020188737A (ja) * | 2019-05-23 | 2020-11-26 | 東ソー株式会社 | 抗体依存性細胞傷害活性が向上した抗体の製造方法 |
| KR102682066B1 (ko) * | 2021-10-12 | 2024-07-05 | 프레스티지바이오로직스 주식회사 | 항체 집단의 제조 방법 |
| WO2025160161A1 (en) * | 2024-01-23 | 2025-07-31 | Amgen Inc. | Methods for modulating monoclonal antibody charge variants |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5705364A (en) | 1995-06-06 | 1998-01-06 | Genentech, Inc. | Mammalian cell culture process |
| JP4306813B2 (ja) | 1995-09-19 | 2009-08-05 | アスビオファーマ株式会社 | 動物細胞の新規培養方法 |
| WO2002076578A1 (en) * | 2001-03-27 | 2002-10-03 | Smithkline Beecham Corporation | Control of glycoforms in igg |
| TWI384069B (zh) * | 2004-08-27 | 2013-02-01 | Pfizer Ireland Pharmaceuticals | 多胜肽之製法 |
| WO2011019619A1 (en) * | 2009-08-11 | 2011-02-17 | Genentech, Inc. | Production of proteins in glutamine-free cell culture media |
| US9045536B2 (en) * | 2009-12-23 | 2015-06-02 | Merck Sharp & Dohme Corp. | Cell line 3M |
| WO2011085095A2 (en) * | 2010-01-07 | 2011-07-14 | Dr. Reddy's Laboratories Ltd. | Enhanced protein expression |
| CA2795461C (en) * | 2010-04-26 | 2018-04-24 | Novartis Ag | Improved cell cultivation process |
| MY163081A (en) * | 2010-12-28 | 2017-08-15 | Chugai Pharmaceutical Co Ltd | Animal cell culturing method |
| KR20150043523A (ko) | 2012-09-02 | 2015-04-22 | 애브비 인코포레이티드 | 단백질 불균일성의 제어 방법 |
-
2014
- 2014-07-07 HK HK16106205.0A patent/HK1218297A1/zh unknown
- 2014-07-07 SG SG11201510342VA patent/SG11201510342VA/en unknown
- 2014-07-07 BR BR112015032800A patent/BR112015032800A2/pt not_active IP Right Cessation
- 2014-07-07 AR ARP140102519A patent/AR096839A1/es unknown
- 2014-07-07 IN IN2285MU2013 patent/IN2013MU02285A/en unknown
- 2014-07-07 US US14/903,093 patent/US20160215319A1/en not_active Abandoned
- 2014-07-07 CA CA2917484A patent/CA2917484A1/en not_active Abandoned
- 2014-07-07 MX MX2016000123A patent/MX2016000123A/es unknown
- 2014-07-07 EP EP14789418.2A patent/EP3019528A1/en not_active Withdrawn
- 2014-07-07 WO PCT/IN2014/000450 patent/WO2015004679A1/en not_active Ceased
- 2014-07-07 EA EA201690171A patent/EA201690171A1/ru unknown
- 2014-07-07 NZ NZ715246A patent/NZ715246A/en not_active IP Right Cessation
- 2014-07-07 JP JP2016522968A patent/JP2016526385A/ja active Pending
- 2014-07-07 TW TW103123312A patent/TW201514305A/zh unknown
- 2014-07-07 AU AU2014288811A patent/AU2014288811B2/en not_active Ceased
- 2014-07-07 CN CN201480038458.4A patent/CN105431454A/zh active Pending
-
2015
- 2015-12-21 IL IL243011A patent/IL243011A0/en unknown
- 2015-12-22 ZA ZA2015/09334A patent/ZA201509334B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HK1218297A1 (zh) | 2017-02-10 |
| JP2016526385A (ja) | 2016-09-05 |
| AU2014288811B2 (en) | 2017-06-08 |
| ZA201509334B (en) | 2017-03-29 |
| MX2016000123A (es) | 2016-07-14 |
| IL243011A0 (en) | 2016-03-31 |
| IN2013MU02285A (enExample) | 2015-06-19 |
| NZ715246A (en) | 2017-07-28 |
| CA2917484A1 (en) | 2015-01-15 |
| CN105431454A (zh) | 2016-03-23 |
| WO2015004679A1 (en) | 2015-01-15 |
| SG11201510342VA (en) | 2016-01-28 |
| US20160215319A1 (en) | 2016-07-28 |
| TW201514305A (zh) | 2015-04-16 |
| AU2014288811A1 (en) | 2016-01-28 |
| BR112015032800A2 (pt) | 2017-07-25 |
| EP3019528A1 (en) | 2016-05-18 |
| AR096839A1 (es) | 2016-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2013MU02285A (enExample) | ||
| BR112019007288A2 (pt) | proteína heterodimérica biespecífica, composições de ácido nucleico e de vetor de expressão, vetor de expressão, célula hospedeira, e, métodos para produzir proteína heterodimérica biespecífica e para tratar câncer em um paciente | |
| ZA201703241B (en) | Anti-c5 antibodies and methods of use | |
| EA201992670A1 (ru) | Способ получения биспецифических антител, биспецифические антитела и терапевтическое применение таких антител | |
| PH12016501212A1 (en) | Human anti-il-33 neutralizing monoclonal antibody | |
| AR096713A1 (es) | Proceso de purificación para anticuerpos monoclonales | |
| PE20210107A1 (es) | Anticuerpos anti-cd3 y metodos de uso | |
| PH12018501282A1 (en) | Anti-c5 antibodies and methods of use | |
| EP4477668A3 (en) | Heterodimeric antibody fc-containing proteins and methods for production thereof | |
| AR106201A1 (es) | Moléculas biespecíficas de unión a antígeno activadoras de células t | |
| CY1118829T1 (el) | Ανασταλτικος vegf σταθερων και διαλυτων αντισωματων | |
| BR112014018961A8 (pt) | Anticorpo isolado, anticorpo biespecífico, fragmento, ácido nucleico isolado, vetor, célula hospedeira, método de produção de anticorpos, composição farmacêutica, uso do anticorpo, método de tratamento, método de inibição e artigo industrializado | |
| EA201300819A1 (ru) | Молекулы антител, которые связываются с il-17a и il-17f | |
| BR112016010706A2 (pt) | anticorpo biespecífico, composição farmacêutica, uso do anticorpo biespecífico, sequência de ácido nucleico, vetor de expressão, célula hospedeira e método de produção de um anticorpo | |
| EA201990894A1 (ru) | Анти-pd-1/анти-her2 гетеродимерное биспецифическое антитело со структурой природного антитела и способ его получения | |
| MX2016016883A (es) | Anticuerpo anti-axl. | |
| EA201891709A1 (ru) | Антигенсвязывающие белки, связывающие pd-l1 | |
| PE20211533A1 (es) | Moleculas biespecificas de unon a antigeno activadoras de celulas t | |
| MX359384B (es) | Conjunto mejorado de anticuerpos bisespecificos. | |
| PH12018502354B1 (en) | Anti-c5 antibodies and methods of use | |
| EA201590550A1 (ru) | Композиции и способы получения гликопротеинов | |
| EA201791275A1 (ru) | Способы получения ctp-модифицированных полипептидов длительного действия | |
| NZ750244A (en) | Humanized antibodies transmigrating the blood-brain barrier and uses thereof | |
| PH12016502406A1 (en) | Cell culture process for producing a protein | |
| ECSP20024551A (es) | ANTICUERPO MONOCLONAL PARA IL-5Ra |